{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:hc.lynparza:6 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Ahc.lynparza%3A6",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.003671,
    "timestamp_received": "2026-04-06T14:51:53.096632+00:00Z",
    "timestamp_returned": "2026-04-06T14:51:53.100303+00:00Z",
    "trace_id": "3d2934db-7c5e-47dd-a102-e0d197deee57"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-03-05"
  },
  "data": [
    {
      "id": "ind:hc.lynparza:6",
      "indication": "LYNPARZA is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. BRCA mutation must be confirmed before LYNPARZA treatment is initiated.",
      "initial_approval_date": null,
      "initial_approval_url": null,
      "description": "Health Canada approved olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.",
      "raw_biomarkers": "germline and/or somatic BRCA mutation",
      "raw_cancer_type": "metastatic castration-resistant prostate cancer (mCRPC)",
      "raw_therapeutics": "Lynparza (olaparib), abiraterone, prednisone or prednisolone",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:hc.lynparza",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Lynparza (olaparib) [product monograph]. HC.",
        "title": null,
        "aliases": [],
        "description": "AstraZeneca Canada Inc. Lynparza (olaparib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00080379.PDF. Published April 2025. Accessed June 2025.",
        "urls": [
          "https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96554",
          "https://pdf.hres.ca/dpd_pm/00080379.PDF"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "hc",
              "type": "Agent",
              "agentType": "organization",
              "name": "Health Canada",
              "description": "Regulatory agency that approves drugs for sale and use in Canada.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-06-11",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://health-products.canada.ca/dpd-bdpp/",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "AstraZeneca Canada Inc.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Lynparza",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "olaparib",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2025-04-29",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2025-04-29",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}